[英] 大卫泰勒（David Taylor
伦敦国王学院药理学教授，南伦敦和莫斯利国民保健基金会信托基金药理和病理学主任。
目錄：
Preface
Acknowledgements
Notes on using The Maudsley Prescribing Guidelines
List of abbreviations
Chapter 1 Plasma level monitoring of psychotropic drugs
Interpreting sample results
Acting on clozapine plasma concentration results
Interpreting post-mortem blood concentrations
Chapter 2 Schizophrenia
ANTIPSYCHOTIC DRUGS
General introduction
General principles of prescribing
Minimum effective doses
Quick reference for licensed maximum doses
Equivalent doses
High‐dose antipsychotics： prescribing and monitoring
Antipsychotic prophylaxis
Combined antipsychotics
Negative symptoms
Monitoring
Relative adverse effects a rough guide
Treatment algorithms for schizophrenia
First‐generation antipsychoticsplace in therapy
Omega‐3 fatty acid fish oils in schizophrenia
New and developing drugs to treat schizophrenia
NICE guidelines for the treatment of schizophrenia
Antipsychotic response to increase the dose, to switch,to add or just wait what is the right move?
Antipsychotic long‐acting injections
Depot antipsychotics pharmacokinetics
Management of patients on long‐term depots
Aripiprazole LAI
Olanzapine LAI
Paliperidone palmitate LAI
Risperidone LAI
ANTIPSYCHOT ICS ADVERS E EFFECTS
Extrapyramidal side‐effects
Akathisia
Weight gain
Treatment of drug‐induced weight gain
Tardive dyskinesia
Neuroleptic malignant syndrome
Catatonia
QT prolongation
Dyslipidaemia
Diabetes and impaired glucose tolerance
Hypertension
Hyponatraemia
Hyperprolactinaemia
Sexual dysfunction
Pneumonia
Switching antipsychotics
REFRACTORY SCHIZOPHRENIA AND CLOZAPINE
Clozapine dosing regimen
Optimising clozapine treatment
Alternatives to clozapine
Re‐starting clozapine after a break in treatment
Initiation of clozapine for community‐based patients
CLOZAPINE ADVERS E EFFECTS
Common adverse effects
Clozapine： uncommon or unusual adverse effects
Clozapine： serious haematological and cardiovascular adverse effects
Clozapine‐induced hypersalivation
Clozapine‐induced gastrointestinal hypomotility CIGH
Clozapine, neutropenia and lithium
Clozapine and chemotherapy
Chapter 3 Bipolar affective disorder
Lithium
Valproate
Carbamazepine
Antipsychotics in bipolar disorder
Treatment of acute mania or hypomania
Bipolar depression
Rapid‐cycling bipolar affective disorder
Prophylaxis in bipolar affective disorder
Physical monitoring for people with bipolar affective disorder
Chapter 4 Depression and anxiety
Introduction
Basic principles of prescribing in depression
Official guidance on the treatment of depression
Antidepressants： general overview
St Johns wort
Recognised minimum effective doses of antidepressants
Drug treatment of depression
Treatment of refractory depression
Psychotic depression
Electroconvulsive therapy and psychotropic drugs
Psychostimulants in depression
Post‐stroke depression
Treatment of depression in the elderly
Antidepressant discontinuation symptoms
Antidepressant prophylaxis
Antidepressants： alternative routes of administration
Antidepressants： swapping and stopping
Drug interactions with antidepressants
Cardiac effects of antidepressants
Antidepressant‐induced arrhythmia
Antidepressant‐induced hyponatraemia
Antidepressants and hyperprolactinaemia
Antidepressants and diabetes mellitus
Antidepressants and sexual dysfunction
SSRIs and bleeding
Antidepressants： relative adverse effects a rough guide
Anxiety spectrum disorders
Benzodiazepines in the treatment of psychiatric disorders
Benzodiazepines： dependence and detoxification
Benzodiazepines and disinhibition
Chapter 5 Children and adolescents
Principles of prescribing practice in childhood and adolescence
Depression in children and adolescents
Bipolar illness in children and adolescents
Psychosis in children and adolescents
Anxiety disorders in children and adolescents
Obsessive compulsive disorder in children and adolescents
Post-traumatic stress disorder in children and adolescents
Attention deficit hyperactivity disorder
Autism spectrum disorders
Tics and Tourettes syndrome
Melatonin in the treatment of insomnia in children and adolescents
Rapid tranquillisation in children and adolescents
Doses of commonly used psychotropic drugs in children and adolescents
Chapter 6 Substance misuse
Introduction
Alcohol dependence
Opioid misuse and dependence
Nicotine and smoking cessation
Pharmacological treatment of dependence on stimulants
Benzodiazepine misuse
GBL and GHB dependence
Drugs of misuse： a summary
Interactions between street drugs and prescribed psychotropic drugs
Chapter 7 Use of psychotropic drugs in special patient groups
The elderly
Dementia
Safer prescribing of physical health medicines in dementia
Management of non-cognitive symptoms of dementia
Parkinsons disease
Multiple sclerosis
Huntingtons disease
Pregnancy
Breastfeeding
Renal impairment
Hepatic impairment
HIV infection
Eating disorders
Acutely disturbed or violent behaviour
Borderline personality disorder
Learning disabilities
Delirium
Epilepsy
Surgery
Velo-cardio-facial syndrome
Cytochrome CYP function
Psychiatric side-effects of non-psychotropic drugs
Atrial fibrillation
Chapter 8 Miscellaneous conditions and substances
Psychotropic drugs in overdose
Biochemical and haematological effects of psychotropics
Prescribing drugs outside their licensed indicationsoff-label prescribing
Observations on the placebo effect in mental illness
Drug interactions with alcohol
Nicotine
Smoking and psychotropic drugs
Caffeine
Complementary therapies
Enhancing medication adherence
Driving and psychotropic medicines
Covert administration of medicines within food and drink
Index
內容試閱：
This 12th edition of The Maudsley Prescribing Guidelines in Psychiatry marks its 20thyear in continuous production. Readers who have owned or used previous editions willfind this edition no different in style from previous incarnations. This is deliberate thefeedback we receive suggests the organisation and structure are well liked. Each sectionof The Guidelines is a densely referenced but succinct review of the literature, set alongsidesome fairly broad recommendations for practice. Each of these sections has beenupdated and revised, and some new ones added for example, interpreting clozapineplasma levels, post‐mortem plasma levels, summary of depot pharmacokinetics. Much of the guidance provided in this edition has changed as a result of more recent research;some of it to a small extent, some of it to an extent amounting to a reversal of priorguidance for example, on the use of fish oils in psychosis. These changes reflect thevery nature of the scientific method that hypotheses come and go as evidence mountsor is countered.
This edition of The Guidelines has a particularly international flavour. This is becausethe 11th edition sold more copies outside the UK than in it, and because there are, wethink, at least ten translations of The Guidelines in existence. Although The Guidelinesare still essentially our local guide to prescribing, we have made a special effort towiden, geographically speaking, its utility. This is most noticeable in the inclusion ofdrugs not licensed in the UK e.g. ziprasidone, iloperidone, desvenlafaxine, but widelyused in other countries. Readers should, therefore, not assume that every drug mentionedin The Guidelines is available in their own country. The reader should also beaware that no guideline could take account of every psychotropic drug used around theworld, so omissions are inevitable.
1.As with previous editions, very special thanks are due to Maria OHagan who managesthe writing and structuring of The Guidelines; an increasingly complex processgiven the size, complexity and heavily referenced nature of the current edition. Thanksare also due to the many expert contributors to The Guidelines who are listed overleaf,and to Adam Gilbert, our editor at Wiley.
David Taylor
購物車/收銀台(0) | 在線留言板
| 付款方式
| 運費計算
| 聯絡我們
| 幫助中心 |
加入書簽
HOME
新書上架
